Cagrilintide studies
164 journal papers mention Cagrilintide in the title or abstract. Here are the most cited, the latest, and a few facts about the literature.
Studies range from laboratory work to clinical trials. A paper listed here is not an endorsement and says nothing about whether Cagrilintide is safe, effective or approved for any use.
- Papers
- 164
- 113 articles, 51 reviews
- Earliest paper
- 2021
- Most papers in 2026 (72)
- Open access
- 58%
- free to read somewhere
- Reviews
- 31%
- of all papers listed
What kind of studies
Of 105 papers in PubMed that mention Cagrilintide in the title or abstract, by the study type PubMed records. Categories overlap, so they do not add up to the total.
- Randomized controlled trials15
- Other clinical trials0
- Meta-analyses and systematic reviews11
- Other reviews50
- Case reports0
- Animal studies only6
- Studies in humans64
Study types are tags assigned by publishers and PubMed indexers; very new papers are often not tagged yet, and a tag is not a quality rating. Retracted papers are excluded. Source: PubMed (NCBI).
Registered clinical studies
Studies on ClinicalTrials.gov that mention Cagrilintide in their intervention details. A registration says a study is planned or running, not what it found.
- Registered
- 44
- Completed
- 24
- Ongoing or planned
- 18
- Phase 1
- 17
- Phase 2
- 5
- Phase 3
- 22
- Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
NCT07607587RecruitingPhase 1started 2026-05-29
- A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
NCT06221969CompletedPhase 3started 2024-01-16
- A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
NCT06534411CompletedPhase 3started 2024-11-05
- A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
NCT07282613RecruitingPhase 3started 2026-08-04
- Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
NCT07220759Active, not recruitingPhase 3started 2025-11-05
The five most recently updated studies. See all 44 on ClinicalTrials.gov. Source: ClinicalTrials.gov (U.S. National Library of Medicine). Studies are found by the compound's name, so a few may be about something else.
Papers per year
2021 to 2026, peak 72 papers in a year. The latest year may still be incomplete.
Where it is published
- Diabetes32 papers
- The Lancet8 papers
- Peptides5 papers
- Diabetes Obesity and Metabolism5 papers
- The Lancet Diabetes & Endocrinology5 papers
The papers
Most citedName in the title
- Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis
Deep Dutta, Lakshmi Nagendra, BG Harish et al. · Indian Journal of Endocrinology and Metabolism · 2024
ReviewOpen access · CC BY-NC-SA17 citationsRead the open copy →
- Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti‐Obesity Medications: A Systematic Review, Meta‐Analysis and Meta‐Regression
Muhammad Ahmed, Muhammad Hassan, Muhammad Tahir et al. · Diabetes Obesity and Metabolism · 2026
Meta-analysis5 citations
- Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis
Hammad Rao, Sumet Kumar, Sheikh Muhammad Ebtehaj Ali et al. · Journal of Diabetes & Metabolic Disorders · 2026
ReviewOpen access2 citationsRead the open copy →
- Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo
Mohammad Yaseen, Akmal Ameer, Zulfiqar Ali et al. · Annals of Medicine and Surgery · 2026
ReviewOpen access · CC BY-NC-NDRead the open copy →
LatestName in title or abstract
- EMERGING PHARMACOLOGICAL STRATEGIES IN OBESITY: FROM GLP-1 AGONISTS THROUGH TRIPLE INCRETIN THERAPY TO AMYLIN ANALOGS – NARRATIVE REVIEW
Dagmara Laufer, Olga Klimczak, Filip Chodań et al. · Archiv Euromedica · 2026
ReviewOpen accessRead the open copy →
- Efficacy and Safety of CagriSema in Type 2 Diabetes: A Dose‐ and Comparator‐Specific Systematic Review and Bayesian Meta‐Analysis
Chia Siang Kow, Abdullah Faiz Zaihan, Dinesh Sangarran Ramachandram et al. · Diabetes Obesity and Metabolism · 2026
ReviewOpen access · CC BYRead the open copy →
- Dose-specific efficacy and safety of cagrisema in type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials
Bilal Wazir Khan, Muhammad Huzaifa Khattak, Muhammad Yahya et al. · BMC Endocrine Disorders · 2026
ReviewOpen access · CC BY-NC-NDRead the open copy →
- CagriSema versus Semaglutide 2.4 mg monotherapy for weight management in adults with overweight or obesity, with or without type 2 diabetes: a systematic review, meta-analysis, and trial sequential analysis
Zehra Khatoon Rasool, Rajvi Shah, Ansharah E Zinnia Batool et al. · Frontiers in Endocrinology · 2026
Meta-analysisOpen access · CC BYRead the open copy →
- Gastrointestinal adverse effects of GLP‐1 receptor agonists and dual GIP/GLP‐1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents
Fnu Vikash, Muhammad Ehsan, Sara Osorio Valencia et al. · Nutrition in Clinical Practice · 2026
ReviewOpen access · CC BY-NCRead the open copy →
- New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus
Theodoros Panou, Evanthia Gouveri, Djordje S. Popovic et al. · Diabetes Therapy · 2026
ReviewOpen access · CC BY-NCRead the open copy →
- Recent Studies on the Effectiveness and Safety of Anti-Obesity Medications: A Scoping Review
Irma Melyani Puspitasari, Dimas Setyadi Putra, Alifa Nisa Deliyana et al. · Diabetes Metabolic Syndrome and Obesity · 2026
ReviewOpen access · CC BY-NCRead the open copy →
- Efficacy and Safety of CagriSema for Metabolic Outcomes: Systematic Review and Pairwise Meta-Analysis of Randomized Controlled Trials
Chuhan Shao, Hanmo Lin, Jie Yu et al. · Diabetes Metabolic Syndrome and Obesity · 2026
ReviewOpen access · CC BY-NCRead the open copy →
- Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes
Areesha Moiz, Kristian B. Filion, Aaron E. Samuels et al. · Annals of Internal Medicine · 2026
Systematic review
- Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials
Bilal Wazir Khan, Syed Asadullah Agha, Ihsan Qamar et al. · Naunyn-Schmiedeberg s Archives of Pharmacology · 2026
Review
- Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs
Sophia L. Fischer, Tito Borner · Pharmacological Research · 2026
ReviewOpen access · CC BYRead the open copy →
- Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials
Deshi Chen, Bing Ma, Hao Sun et al. · BMJ Medicine · 2026
ReviewOpen access · CC BY-NCRead the open copy →
- Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early‐Phase Clinical Trials
Abdulhameed Alhazmi, Carel Wynand le Roux · Diabetes Obesity and Metabolism · 2026
ReviewOpen access · CC BY-NC-ND1 citationsRead the open copy →
- Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo
Mohammad Yaseen, Akmal Ameer, Zulfiqar Ali et al. · Annals of Medicine and Surgery · 2026
ReviewOpen access · CC BY-NC-NDRead the open copy →
- Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis
Kailei Nong, Qingyang Shi, Xinran Xie et al. · BMJ · 2026
Systematic reviewOpen access · CC BY-NC10 citationsRead the open copy →
Each list shows up to 40 papers.See all 164 on OpenAlex. Source: OpenAlex (CC0), journal articles and reviews with a DOI, retractions excluded, refreshed weekly, last 4 Nov 2026, 08:31 UTC. Papers are listed by their metadata only; follow the links to read them. A license shown on an open copy is the license the publisher or repository states for that copy.